Targeted therapies in metastatic renal cell carcinoma: The light at the end of the tunnel

Expert Review of Anticancer Therapy

Volumn 6, Issue 12, 2006, Pages 1761-1767

  Pouessel, Damien ^a   Culine, Stépane ^a  

^a CENTRE VAL D AURELLE   (France)

Author keywords

Bevacizumab; Immunotherapy; mTOR; Renal cell carcinoma; Sorafenib; Sunitinib; VEGF

Indexed keywords

ALPHA INTERFERON; BEVACIZUMAB; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; EVEROLIMUS; GEFITINIB; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INTERFERON; INTERLEUKIN 2; LAPATINIB; MAMMALIAN TARGET OF RAPAMYCIN; MEDROXYPROGESTERONE ACETATE; PANITUMUMAB; PLACEBO; SORAFENIB; SUNITINIB; TEMSIROLIMUS; TORISEL; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR; VINBLASTINE; VON HIPPEL LINDAU PROTEIN;

ANEMIA; ASTHENIA; CANCER HORMONE THERAPY; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CLEAR CELL CARCINOMA; CLINICAL TRIAL; CONTINUOUS INFUSION; CYTOREDUCTIVE SURGERY; DIARRHEA; DISEASE FREE SURVIVAL; DRUG DOSE COMPARISON; DRUG ERUPTION; DRUG MECHANISM; DRUG MEGADOSE; DRUG PROTEIN BINDING; DRUG RECEPTOR BINDING; DRUG TARGETING; DYSPNEA; FATIGUE; GENE INACTIVATION; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; KIDNEY CARCINOMA; LOW DRUG DOSE; METASTASIS; MONOTHERAPY; NEPHRECTOMY; OVERALL SURVIVAL; PROGNOSIS; PROTEINURIA; REVIEW; UNSPECIFIED SIDE EFFECT;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENZENESULFONATES; BIOLOGICAL RESPONSE MODIFIERS; CARCINOMA, RENAL CELL; CHEMOTHERAPY, ADJUVANT; DRUG DELIVERY SYSTEMS; DRUG THERAPY, COMBINATION; FORECASTING; HUMANS; IMMUNOTHERAPY; INDOLES; INTERFERON-ALPHA; INTERLEUKIN-2; KIDNEY NEOPLASMS; NEOPLASM PROTEINS; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; PYRIDINES; PYRROLES; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; SIROLIMUS;

EID: 33846084359     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.6.12.1761     Document Type: Review

References (42)

1. Jemal A, Murray T, Ward E et al. Cancer statistics, 2005. CA Cancer J. Clin. 55, 10-30 (2005).
2. Pantuck AJ, Zisman A, Belldegrun AS. The changing natural history of renal cell carcinoma. J. Urol. 166, 1611-1623 (2001).
3. Linehan WM, Walther MM, Zbar B. The genetic basis of cancer of the kidney. J. Urol. 170, 2163-2172 (2003).
4. Storkel S, Eble JN, Adlakha K et al. Classification of renal cell carcinoma: workgroup no 1. Union Internationale Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC). Cancer 80, 987-989 (1997).
5. Motzer RJ, Russo P. Systemic therapy for renal cell carcinoma. J. Urol. 163, 408-417 (2000).
6. Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J. Clin. Oncol. 17, 2530-2540 (1999).
7. Medical Research Council Renal Cancer Collaborators. Interferon-α and survival in metastatic renal carcinoma: early results of a randomised controlled trial. Lancet 353, 14-17 (1999).
8. Pyrhönen S, Salminen E, Ruutu M et al. Prospective randomized trial of interferon α-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer. J. Clin. Oncol. 17, 2859-2867 (1999).
9. Mickisch GHJ, Garin A, van Poppel H, de Prijck L, Sylvester R. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet 358, 966-970 (2001).
10. Flanigan RC, Salmon SE, Blumenstein BA et al. Nephrectomy followed by interferon α-2b compared with interferon α-2b alone for metastatic renal-cell cancer. N. Engl. J. Med. 345, 1655-1659 (2001).
11. Flanigan RC, Mickisch G, Sylvester R, Tangen C, van Poppel H, Crawford ED. Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. J. Urol. 171, 1071-1076 (2004).
12. Négrier S, Escudier B, Lasset C et al. Recombinant human interleukine-2, recombinant human interferon α-2a, or both in metastatic renal cell carcinoma. N. Engl. J. Med. 338, 1272-1278 (1998).
13. Négrier S, Pérol D, Ravaud A et al. Is intravenous IL2 superior to subcutaneous IL2 in good prognosis patients with metastatic renal cell carcinoma receiving a combination of IL2 and α-interferon? Results of the prospective randomized PERCY Duo trial. Proc. Am. Soc. Clin. Oncol. 24, S225 (2006) (Abstract 4536).
14. Négrier S, Pérol D, Ravaud A et al. Do cytokines improve survival in patients with metastatic renal cell carcinoma of intermediate prognosis? Results of the prospective randomized PERCY Quattro trial. Proc. Am. Soc. Clin. Oncol. 23, S1093 (2005) (Abstract 4511).
15. Yang JC, Sherry RM, Steinberg SM et al. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J. Clin. Oncol. 21, 3127-3132 (2003).
16. McDermott DF, Regan MM, Clark JI et al. Randomized Phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 23, 133-141 (2005).
17. Motzer RJ, Bacik J, Murphy BA, Russo RP, Mazumdar M. Interferon-α as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J. Clin. Oncol. 20, 289-296 (2002).
18. Négrier S, Escudier B, Gomez F et al. Prognostic factors of survival and rapid progression in 782 patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Français d'Immunothérapie. Ann. Oncol. 13, 1460-1468 (2002).
19. Bui MH, Seligson D, Han KR et al. Carbonic anhydrase IX is an independent predictor of survival in advanced renal cell carcinoma: implications for prognosis and therapy. Clin. Cancer Res. 9, 802-811 (2003).
20. Négrier S, Pérol D, Ménétrier-Caux C et al. Interieukin-6, interleukin-10 and vascular endothelial growth factor in metastatic renal cell carcinoma: prognostic value of interleukin-6. J. Clin. Oncol. 22, 2371-2378 (2004).
21. Bukowski RM, Négrier S, Elson P. Prognostic factors in patients with advanced renal cell carcinoma: development of an International Kidney Cancer Working Group. Clin. Cancer Res. 10, S6310-S6314 (2004).
22. Rathmell WK, Wright TM, Rini BI. Molecularly targeted therapy in renal cell carcinoma. Expert Rev. Anticancer Ther. 5, 1031-1040 (2005).
23. Ratain MJ, Risen T, Stadler WM et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 24, 2505-2512 (2006).
24. Escudier B, Szczylik C, Eisen T et al. Randomized Phase III trial of the Raf kinase and VEGF inhibitor sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma. Proc. Am. Soc. Clin. Oncol. 23, 1093S (2005) (Abstract 4510).
25. Motzer RJ, Michaelson MD, Redman BG et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 24, 16-24 (2006).
26. Motzer RJ, Rini BI, Bukowski RM et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 295, 2516-2524 (2006).
27. Motzer RJ, Hutson TE, Tomczak P et al. Phase III randomized trial of sunitinib malate (SU11248) versus interferon-α (IFN-α) as first-line systemic therapy for patients with metastatic renal cell carcinoma. Proc. Am. Soc. Clin. Oncol. 24, S930 (2006) (Abstract LBA3).
28. Yang JC, Haworth L, Sherry RM et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N. Engl. J. Med. 349, 427-434 (2003).
29. Hudson CC, Liu M, Chiang GG et al. Regulation of hypoxia-inducible factor 1α expression and function by the mammalian target of rapamycin. Mol. Cell. Biol. 22, 7004-7014 (2002).
30. Skotnicki JS, Leone CL, Smith AL. Design, synthesis, and biological evaluation of C-42 hydroxyesters of rapamycin: the identification of CCI-779. Clin. Cancer Res. 7, S3749-S3750 (2001).
31. Atkins MB, Hidalgo M, Stadler WM et al. Randomized Phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J. Clin. Oncol. 22, 909-918 (2004).
32. Hudes G, Carducci M, Tomczak P et al. A Phase 3, randomized, 3-arm study of temsirolimus (TEMSR) or interferon-α (IFN) or the combination of TEMSR + IFN in the treatment of first-line, poor-risk patients with advanced renal cell carcinoma. Proc. Am. Soc. Clin. Oncol. 24, S930 (2006) (Abstract LBA4).
33. Amato RJ, Misellati A, Khan M, Chiang S. A Phase II trial of RAD001 in patients with metastatic renal cell carcinoma. Proc. Am. Soc. Clin. Oncol. 24, S224 (2006) (Abstract 4530).
34. Motzer RJ, Amato R, Todd M et al. Phase II trial of antiepidermal growth factor receptor antibody C225 in patients with advanced renal cell carcinoma. Invest. New Drugs 21, 99-101 (2003).
35. Drucker B, Bacik J, Ginsberg M et al. Phase II trial of ZD1839 in patients with advanced renal cell carcinoma. Invest. New Drugs 21, 341-345 (2003).
36. Dawson NA, Guo C, Zak R et al. A Phase II trial of gefitinib (Iressa, ZD1839) in stage IV and recurrent renal cell carcinoma. Clin. Cancer Res. 10, 7812-7819 (2004).
37. Rowinsky EK, Schwartz GH, Gollob JA et al. Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer. J. Clin. Oncol. 22, 3003-3015 (2004).
38. Beeram M, Rowinsky EK, Weiss GR et al. Durable disease stabilization and antitumor activity with OSI-774 in renal cell carcinoma: a Phase II, pharmacokinetic and biological correlative study with FDG-PET imaging. Proc. Am. Soc. Clin. Oncol. 22, S207 (2004) (Abstract 3050).
39. Ravaud A, Gardner J, Hawkins R et al. Efficacy of lapatinib in patients with high tumor EGFR expression: results of a Phase III trial in advanced renal cell carcinoma. Proc. Am. Soc. Din. Oncol. 24, S217 (2006) (Abstract 4502).
40. Azad NS, Posadas EM, Kwitkowski E et al. Increased efficacy and toxicity with combination anti-VEGF therapy using sorafenib and bevacizumab. Proc. Am. Soc. Clin. Oncol. 24, S121 (2006) (Abstract 3004).
41. Hainsworth JD, Sosman JA, Spigel DR, Edwards DL, Baughman C, Greco A. Treatment of metastatic renal cell carcinoma with combination of bevacizumab and erlotinib. J. Clin. Oncol. 23, 7889-7896 (2005).
42. Bukowski RM, Kabbinavar F, Giglin RA et al. Bevacizumab with or without relotinib in metastatic renal cell carcinoma. Proc. Am. Soc. Clin. Oncol. 24, S222 (2006) (Abstract 4523).